Comparative Pharmacology
Head-to-head clinical analysis: NORPACE versus PROCAINAMIDE HCL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORPACE versus PROCAINAMIDE HCL.
NORPACE vs PROCAINAMIDE HCL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Class Ic antiarrhythmic agent; blocks voltage-gated sodium channels, slowing conduction velocity and prolonging refractory periods in cardiac tissue.
Class Ia antiarrhythmic agent; blocks sodium channels, decreases phase 0 slope of action potential, prolongs refractory period, and increases action potential duration.
150 mg orally every 6 hours (maximum 300 mg per dose), extended-release formulation 300 mg every 12 hours.
For life-threatening ventricular arrhythmias, IV: Loading dose: 100 mg administered at a rate of 25-50 mg/min, may repeat every 5 minutes until arrhythmia suppressed or up to a total of 500-1000 mg. Maintenance: IV infusion 1-4 mg/min. Oral: 250-500 mg every 3-6 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life: 6-8 hours (normal renal function); prolonged in renal impairment (up to 24 hours).
Terminal elimination half-life: 2.5-4.7 hours (3 hours typical) in normal renal function; prolonged to 11-20 hours in renal impairment; NAPA half-life 6-8 hours (prolonged in renal failure).
Renal: 40-60% unchanged; biliary/fecal: minor (10-20%).
Primarily renal (50-60% unchanged via glomerular filtration and tubular secretion) with 10-30% as N-acetylprocainamide (NAPA) metabolite; minor biliary/fecal (<5%).
Category C
Category A/B
Antiarrhythmic (Class Ia)
Antiarrhythmic (Class Ia)